CEL-SCI Corporation
CVM · AMEX
Market closed$1.17$0.020000 (+1.74%)After hours $1.26 · +7.69%
Key statistics
Previous close$1.15
Open$1.13
Day high$1.17
Day low$1.09
52-week high$13.48
52-week low$0.890000
Market cap8.04M
Volume453.98K
Average volume539.65K
P/E ratio-0.22
Forward P/E—
EPS-5.41
Dividend yield0.00%
Market context
Why it moved
CVM edged higher on modest volume likely driven by positive sentiment following news that Brazil's securities regulator (also abbreviated CVM) is taking proactive steps to regulate securities tokenization, potentially boosting broader investor interest in the company.
What is happening
Recent company-specific developments and publisher coverage.
The National Law Review · July 17, 2026CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026Business Wire · July 13, 2026CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck CancerInvesting.com · July 13, 2026CEL-SCI launches confirmatory study for head and neck cancer drugStock Titan · July 13, 2026Cancer drug Multikine heads into 212-patient global trial for head and neck tumorsInvesting News Network · July 13, 2026CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck CancerStock Titan · July 2, 2026Equity plans and pay votes at CEL-SCI (NYSE: CVM) 2026 annual meetingStock Titan · June 24, 2026CEL-SCI and Saudi Amarox seal Multikine pact at BIO 2026Business Wire · May 18, 2026CEL-SCI Reports Fiscal Second Quarter 2026 Results Mt Newswire · July 13, 2026CEL-SCI to Launch Confirmatory Study of Multikine Benzinga · July 13, 2026CEL-SCI To Launch Phase 3 Confirmatory Study Mt Newswire · June 16, 2026CEL-SCI Closes $2.5 Million Stock Offering Benzinga · June 16, 2026CEL-SCI Announces Dual-Track Strategy To Bring Multikine To Patients With Head And Neck Cancer Through Parallel Regulatory Pathways In The U.S. And Saudi Arabia Benzinga · June 12, 2026CEL‑SCI To Sign Saudi Amarox Deal At BIO International Convention 2026, Advancing Multikine Commercialization In Saudi Arabia Mt Newswire · May 18, 2026Cel Sci Insider Bought Shares Worth $360,000, According to a Recent SEC Filing Benzinga · May 15, 2026CEL-SCI Q2 EPS $(0.67) Down From $(0.08) YoY Benzinga · May 11, 2026CEL-SCI Signs Strategic Partnership, Distribution, And Revenue Sharing Agreement With Amarox For Regulatory Affairs, Marketing And Potential Commercialization Of Multikine In Treatment Of Head And Neck Cancer In Saudi Arabia